ABI-H0731

DRUG6 trials

Sponsors

Assembly Biosciences

Conditions

Chronic Hepatitis B

Phase 1

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

CompletedNCT02908191

Assembly BiosciencesChronic Hepatitis B

Start: 2016-11-30End: 2018-06-12Updated: 2019-04-04

Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B

CompletedNCT03109730

Assembly BiosciencesChronic Hepatitis B

Start: 2017-06-15End: 2018-06-12Updated: 2018-07-06

Phase 2

A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection

CompletedNCT03576066

Assembly BiosciencesChronic Hepatitis B

Start: 2018-06-11End: 2019-07-05Updated: 2021-02-17

A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

CompletedNCT03577171

Assembly BiosciencesChronic Hepatitis B

Start: 2018-06-19End: 2019-06-21Updated: 2021-01-28

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

TerminatedNCT04454567

Assembly BiosciencesChronic Hepatitis B

Start: 2020-11-11End: 2021-04-08Updated: 2022-10-20

A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection

TerminatedNCT04781647

Assembly BiosciencesChronic Hepatitis B

Start: 2021-02-18End: 2022-12-02Updated: 2023-10-06

Related Papers

Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses.

2024-01-183 citations

Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

Journal of Hepatology2022-06-1138 citations

Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.

2022-04-2030 citations

Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.

2019-11-0982 citations